About Bavarian Nordic

Company Description

For us, it is all about improving and saving lives
Improving and saving lives through innovative vaccines is at the heart of what we do in Bavarian Nordic, and we have more than 25 years of experience in developing life-saving vaccines. We are a fully integrated vaccines company focused on the development, manufacturing and commercialization of our vaccines, and our vision is to become one of the largest pure play vaccine companies in the world.

We are a global leader in smallpox and monkeypox vaccines and our commercial product portfolio contains market-leading vaccines against rabies and tick-borne encephalitis as well as an Ebola vaccine, which is developed using our live virus vaccine platform technology, MVA-BN®. Our late-stage pipeline comprises a novel COVID-19 vaccine for boosting existing immunity and a vaccine against respiratory syncytial virus (RSV), for which no approved vaccines exist today.

Year founded

1994

Headcount

900

Headquarters

Philip Heymans Alle 3, 2900 Hellerup – Denmark

Shareholder information

Shares outstanding

70,694,315

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Copenhagen

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.